NanoMediTech, a South Korean biotech pharmaceuticals and chemicals company is planning to invest US$2 million into an emerging Indian biotech company.
Online PR News – 20-February-2020 – DONGJAK-GU/SEOUL – NanoMediTech plan an investment of approximately U$2 million and will help NanoMediTech expand its global clinical network and drug-development pipeline.
The Indian biotech company which is based on the outskirts of Mumbai, will be focusing on pharmaceuticals research and development for treatments such as antivirals, antibiotics, antihistamines and antidiabetics.
NanoMediTech’s Chief Science Officer, Mr. Laurent Brunet commented on the Indian investment saying “India is a vibrant pharmaceutical development market and that is a key attraction. The investment will support market expansion and product diversification and also creates the potential to undertake research capabilities in India in collaboration with research institutes.”
“Launching a subsidiary in India is a part of our efforts to expand drug development pipelines. Korea is India’s fourth-largest trade partner, and Korean pharmaceuticals companies are active investors in multiple aspects in India’s pharmaceuticals industries”, added Laurent Brunet, Chief Science Officer of NanoMediTech.
About Us - NanoMediTech
Based in Seoul, Republic of Korea, NanoMediTech is a research and development company developing nanotechnology based biomedical applications. The company is leveraging its proprietary nanotechnologies to develop radically improved medical tools and solutions for the treatment of debilitating diseases and improvement of medical practices.
Nanotechnology is a burgeoning industry with practically limitless applications on our lives and with the potential to revolutionize the manner in which we detect and treat diseases and damage to the human body.